This Article  • References  • Full text PDF  • Correction  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Experience With This Type B Monoamine Oxidase Inhibitor in 200 Patients

Teresita S. Elizan, MD; Melvin D. Yahr, MD; Daniel A. Moros, MD; Marina R. Mendoza, MD; Stuart Pang, MD; Carole A. Bodian, DrPH

Arch Neurol. 1989;46(12):1280-1283.

Abstract
• Two hundred patients at a median age of 63 years, receiving conventional levodopa therapy for 8 years, who had had Parkinson's disease for 10 years, tried a regimen of selegiline (L-deprenyl), a type B monoamine oxidase inhibitor, at a daily dose of 10 mg, for varying periods from less than 6 months to more than 24 months (28% over 24 months). Selegiline does improve parkinsonism during the initial 6 months to 12 to 24 months of combined therapy in one third to almost half of patients with an end-of-dose type of response to long-term levodopa therapy. However, even this particular class of patients is unable to maintain such an improvement by 36 months, much less by 48 months, from the start of the selegiline trial. About one quarter of poor responders to levodopa and those with random deterioration show improvement in their parkinsonian status in the first 6 months of the selegiline trial, but their conditions quickly deteriorate by 1 year. The predominant pattern of response to previous levodopa therapy and the severity of the total disability score at the initiation of the selegiline trial were the two variables that were predictive of risk of failure with the drug. No evidence suggested that selegiline decreases the excess mortality rate of Parkinson's disease above that achieved with the use of levodopa alone. Selegiline as an adjunctive agent to conventional levodopa therapy was not unduly impressive with regard to preventing progression of Parkinson's disease.

Author Affiliations
From the Departments of Neurology (Drs Elizan, Yahr, Moros, Mendoza, and Pang) and Biomathematical Sciences (Dr Bodian), The Mount Sinai Medical Center of the City University of New York.

Footnotes
Accepted for publication May 10, 1989.

Read in part before the Ninth International Symposium on Parkinson's Disease, Jerusalem, Israel, June 9, 1988.

Reprint requests to Department of Neurology, Box 1137, The Mount Sinai Medical Center, 1 Gustave L Levy PI, New York, NY 10029 (Dr Elizan).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Selegiline in Parkinson's disease
Calne
BMJ 1995;311:1583-1584.
FULL TEXT  

High-Dose Selegiline in Treatment-Resistant Older Depressive Patients
Sunderland et al.
Arch Gen Psychiatry 1994;51:607-615.
ABSTRACT  

Early Therapy for Parkinson's Disease-Reply
Elizan et al.
Arch Neurol 1991;48:1009-1010.
ABSTRACT  

Early Combination of Selegiline and Low-Dose Levodopa as Initial Symptomatic Therapy in Parkinson's Disease: Experience in 26 Patients Receiving Combined Therapy for 26 Months
Elizan et al.
Arch Neurol 1991;48:31-34.
ABSTRACT